ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2023
Challenges for Plasma-Derived Medicinal Products.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The effect of plasma donation frequency on total serum protein, immunoglobulin G and donor safety: A non-inferiority randomized controlled trial.Vox sanguinis · 2025Trial
- Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial.Nature medicine · 2025Trial
- Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.Blood advances · 2024Trial
- Plasma donation rates and infection risk: A multicentre observational study in Denmark.Vox sanguinis · 2026Observational
- Current practices for recruitment and retention of plasma donors across 17 countries: A short report.Vox sanguinis · 2026Article
- Apheresis Medicine as a Multidisciplinary Subspecialty: International Models for Training, Quality, and Professional Societies.Journal of clinical apheresis · 2026Review
- Protection of fundamental human rights by improving patient access to plasma-derived therapies and donor health protection.Vox sanguinis · 2026Review
- A Pichia pastoris-based platform for large-scale production of functional recombinant human serum albumin with therapeutic efficacy.Bioprocess and biosystems engineering · 2026Article
- Plasma-based strategies for systemic rejuvenation: critical perspectives on clinical translation.GeroScience · 2026Review
- Review
- Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages.Vox sanguinis · 2025Review
- Report of the Ninth Asian National Control Laboratory Network meeting in 2024, with a focus on regional harmonization of regulatory systems to prepare for cross-border transfer of plasma.Biologicals : journal of the International Association of Biological Standardization · 2025Article
- A relational approach to understanding the factors influencing new plasma donor retention in Canada.Vox sanguinis · 2025Article
- Building awareness: Introducing education about blood-product donation in the school curriculum.Transfusion · 2025Article
- Securing commitment and control for the supply of plasma derivatives for public health systems. I: A short review of the global landscape.Vox sanguinis · 2025Review
- [Strategic independence: a value model for improving access to plasma-derived medicines in Latin AmericaIndependência estratégica: modelo de valor para melhorar o acesso a hemoderivados na América Latina].Revista panamericana de salud publica = Pan American journal of public health · 2025Article
- An ecosystem of interconnected technologies to increase efficiencies in blood establishments: The example of the Blood and Tissue Bank of Aragón, Spain.Vox sanguinis · 2025Article
- The invisible lifeline: Intricacies of the global plasma supply.American journal of hematology · 2024Article
- Toward a Sociology of Plasma Products.International journal of social determinants of health and health services · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasma-derived medicinal products (PDMPs) are medicinal products derived from human plasma, and a number of PDMPs are listed on the WHO Model List of Essential Medicines. These and other PDMPs are crucial for the prophylaxis and treatment of patients with immune deficiencies, autoimmune and inflammatory diseases, bleeding disorders, and a variety of congenital deficiency disorders. The majority of plasma supplies for manufacturing of PDMPs is coming from the USA. Summary: The future of treatments with PDMPs for PDMP-dependent patients depends on the supply of plasma. An imbalance in the global collection of plasma has resulted in regional and global shortages of essential PDMPs. The challenges at different level are mainly related on a balanced and sufficient supply in order to help the patients in need and should be addressed in order to safeguard the treatment with these essential lifesaving and disease mitigating medicines. Key Messages: It is advocated to consider plasma as a strategic resource comparable to energy and other rare resources and to investigate whether for the treatment of patients with rare diseases, a free market of PDMPs has its limitations and special protection measures should be developed. At the same time, plasma collections should be increased outside the USA, including in low- and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.